SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a potential acquisition of eBay, a move seen by the community as a bold, if ambitious, attempt to leverage GameStop's cash reserves for a massive retail transformation. While bullish investors are celebrating the news as a long-awaited catalyst and potential squeeze signal, skeptics are actively questioning the feasibility of financing a deal for a company significantly larger than GameStop itself.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is considering a takeover offer, sparking intense community debate over the feasibility of a bid given the companies' disparate market caps. While retail traders are actively debating the potential for a massive short squeeze or an aggressive e-commerce pivot, many remain skeptical of the deal's structure and execution.

WorldFinancial

World Liberty Financial is facing intense backlash and downward price pressure as investors react to a government probe into its $500 million UAE deal and community concerns over governance voting. While some retail supporters are aggressively buying the dip in hopes of a short squeeze, many are actively labeling the project a grift or pump-and-dump scheme due to recent token dilution and management's perceived lack of transparency.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is capturing significant community attention as traders analyze the stock's consolidation patterns near key resistance levels, with speculation mounting over potential M&A activity and the company's critical role in the booming AI data training sector. Investors are closely monitoring the technical setup for a possible breakout while actively debating the impact of increased institutional options activity and the company's strategic positioning within the evolving AI infrastructure landscape.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech is seeing significant momentum and retail interest driven by a recent reverse split and its status as a low-float play in the Chinese stock sector. The community is actively debating the stock's potential for a parabolic squeeze versus concerns regarding its long-term financial health and potential for future dilution.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge driven by aggressive short-squeeze dynamics, as traders bet on a forced covering of heavy short positions ahead of the upcoming earnings release. The community is actively discussing the stock's potential for further upward momentum, pointing to high borrowing costs and the company's recent expansion in voice AI technology as catalysts to sustain this rally.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors debate the sustainability of its dividend strategy and its high correlation to MicroStrategy's volatility, leading to intense community discussion regarding NAV erosion and the impact of recent reverse stock splits. Market participants are actively comparing the fund's income potential against the underlying asset's performance, with many questioning whether the current dividend yields justify the ongoing price depreciation.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors weigh its role as a key substrate supplier for AI-focused data centers against concerns over its parabolic valuation and recent share dilution. The community remains sharply divided, with bulls pointing to institutional interest and the critical nature of its indium phosphide technology, while bears highlight the company's lack of consistent profitability and reliance on FOMO-driven retail participation.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as institutional accumulation intensifies, highlighted by major treasury purchases from firms like BitMine and continued institutional interest via spot ETFs. Market participants are actively debating the potential impact of the proposed Clarity Act on regulatory sentiment while monitoring whether these sustained inflows and staking dynamics can drive a breakout above key psychological resistance levels.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently seeing significant community interest driven by high-volume options activity and speculation surrounding potential battery supply partnerships for next-generation AR hardware. Traders are closely monitoring key support levels near all-time lows while debating the long-term feasibility of the company's manufacturing scaling efforts.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

<ul class="summary-bullets"><li>Underwriters were given a 30-day option to purchase up to 1.74 million additional shares.</li><li>Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary fibrosis.</li><li>The company plans to launch two late-stage clinical trials starting in the second quarter of 2026.</li></ul>Shares of Trevi Therapeutics, Inc. (TRVI) jumped 5% on Friday to an all-time high after the biotech firm priced its $150 million underwritten public offering at $13 per share.<a href="https://stocktwits.com/symbol/TRVI">TRVI shares</a> are heading for a fifth consecutive session of gains, rising nearly 20% over the course of the rally.While Trevi offered 11.6 million shares at $13 per share, it also granted underwriters a 30-day option to purchase up to 1.74 million additional shares that could fetch up to $22.5 million. The offering is expected to close around April 20, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier. Message volumes soared a whopping 600% on the platform over the past 24 hours, according to Stocktwits data.One user called the price action “strange” and questioned if it was driven by a “small squeeze.”<stembedurl>https://stocktwits.com/abcdzepeda/message/650605154</stembedurl>Another user, who commented before the $13 per share offer was disclosed, said the dilution seemed unnecessary.<stembedurl>https://stocktwits.com/socalBB/message/650528771</stembedurl><h2 class="st-heading-2">Trevi Prepares To Launch Late-Stage Trials For Chronic Cough Treatment</h2>Trevi Therapeutics is currently developing Haduvio, its treatment for chronic cough in patients with conditions such as idiopathic pulmonary fibrosis, interstitial lung disease, and refractory chronic cough.Last month, the firm <a href="https://stocktwits.com/news-articles/markets/equity/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE">announced</a> plans to launch two late-stage clinical trials for Haduvio following discussions with the U.S. Food and Drug Administration (FDA). The first trial is expected to begin in the second quarter of 2026, with the second starting later in the year.Both studies will be randomized and placebo-controlled, testing the drug’s safety and effectiveness. One trial will enroll around 300 patients, while the other will include about 130, Trevi added.The stock has seen heavy buying interest over the past year, surging more than 165%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Equity

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

What's Going On With Trevi Therapeutics Stock?

Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.read more...

Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Hastings' departure. Other stocks also dip in pre-market.read more...

Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High - Time to Buy?

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month High - Still a Buy...

Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2% - Here's What Happened

Trevi Therapeutics (NASDAQ:TRVI) Trading 7.2% Higher - Time to Buy...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRVI News

TRVITrevi Therapeutics Inc